Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1961 2
1974 1
1975 1
1977 1
1980 1
1981 1
1989 4
1990 3
1991 2
1992 9
1993 3
1994 10
1995 9
1996 2
1997 11
1998 7
1999 9
2000 7
2001 8
2002 10
2003 8
2004 4
2005 7
2006 7
2007 8
2008 11
2009 9
2010 7
2011 12
2012 16
2013 12
2014 13
2015 21
2016 14
2017 12
2018 12
2019 13
2020 15
2021 17
2022 5
2023 8
2024 10

Text availability

Article attribute

Article type

Publication date

Search Results

319 results

Results by year

Filters applied: . Clear all
Page 1
Real-world data on the efficacy and safety of immune-checkpoint inhibitors in elderly patients with non-small cell lung cancer.
Morinaga D, Asahina H, Ito S, Honjo O, Tanaka H, Honda R, Yokouchi H, Nakamura K, Takamura K, Hommura F, Kawai Y, Ito K, Sukoh N, Yokoo K, Morita R, Harada T, Takashina T, Goda T, Dosaka-Akita H, Isobe H; Hokkaido Lung Cancer Clinical Study Group Trial. Morinaga D, et al. Among authors: yokouchi h. Cancer Med. 2023 May;12(10):11525-11541. doi: 10.1002/cam4.5889. Epub 2023 Mar 31. Cancer Med. 2023. PMID: 36999734 Free PMC article.
Marine microalgae.
Matsunaga T, Takeyama H, Miyashita H, Yokouchi H. Matsunaga T, et al. Among authors: yokouchi h. Adv Biochem Eng Biotechnol. 2005;96:165-88. doi: 10.1007/b135784. Adv Biochem Eng Biotechnol. 2005. PMID: 16566091 Review.
Pneumonitis associated with pembrolizumab plus chemotherapy for non-squamous non-small cell lung cancer.
Fujimoto D, Miura S, Tomii K, Sumikawa H, Yoshimura K, Wakuda K, Oya Y, Yokoyama T, Kijima T, Asao T, Tamiya M, Nakamura A, Yoshioka H, Tokito T, Murakami S, Tamiya A, Yokouchi H, Watanabe S, Yamaguchi O, Morinaga R, Jodai T, Ito K, Shiraishi Y, Kogure Y, Shibaki R, Yamamoto N. Fujimoto D, et al. Among authors: yokouchi h. Sci Rep. 2023 Mar 6;13(1):3698. doi: 10.1038/s41598-023-30676-y. Sci Rep. 2023. PMID: 36878936 Free PMC article.
Durvalumab after chemoradiotherapy in non-small cell lung cancer with EGFR mutation: A real-world study (HOT2101).
Tsuji K, Mizugaki H, Yokoo K, Kobayashi M, Kawashima Y, Kimura N, Yokouchi H, Kikuchi H, Sumi T, Kawai Y, Kobashi K, Morita R, Ito K, Kitamura Y, Minemura H, Nakamura K, Aso M, Honjo O, Tanaka H, Takashina T, Tsurumi K, Sugisaka J, Tsukita Y, Konno S, Oizumi S. Tsuji K, et al. Among authors: yokouchi h. Cancer Sci. 2024 Apr;115(4):1273-1282. doi: 10.1111/cas.16094. Epub 2024 Jan 29. Cancer Sci. 2024. PMID: 38287788 Free PMC article.
Clinical outcomes in patients with non-small cell lung cancer harboring EGFR Exon20 in-frame insertions in the near-loop and far-loop: Results from LC-SCRUM-Asia.
Okahisa M, Udagawa H, Matsumoto S, Kato T, Yokouchi H, Furuya N, Kanemaru R, Toyozawa R, Nishiyama A, Ohashi K, Miyamoto S, Nishino K, Nakamura A, Iwama E, Niho S, Oi H, Sakai T, Shibata Y, Izumi H, Sugiyama E, Nosaki K, Umemura S, Zenke Y, Yoh K, Kah Mun Low G, Zhuo J, Goto K. Okahisa M, et al. Among authors: yokouchi h. Lung Cancer. 2024 May;191:107798. doi: 10.1016/j.lungcan.2024.107798. Epub 2024 Apr 23. Lung Cancer. 2024. PMID: 38669727
The Tumor Immune Microenvironment Is Associated With Recurrence in Early-Stage Lung Adenocarcinoma.
Kanemura H, Yokoyama T, Nakajima R, Nakamura A, Kuroda H, Kitamura Y, Shoda H, Mamesaya N, Miyata Y, Okamoto T, Okishio K, Oki M, Sakairi Y, Chen-Yoshikawa TF, Aoki T, Ohira T, Matsumoto I, Ueno K, Miyazaki T, Matsuguma H, Yokouchi H, Otani T, Ito A, Sakai K, Chiba Y, Nishio K, Yamamoto N, Okamoto I, Nakagawa K, Takeda M. Kanemura H, et al. Among authors: yokouchi h. JTO Clin Res Rep. 2024 Mar 8;5(4):100658. doi: 10.1016/j.jtocrr.2024.100658. eCollection 2024 Apr. JTO Clin Res Rep. 2024. PMID: 38651033 Free PMC article.
Cyclic AMP is both a pro-apoptotic and anti-apoptotic second messenger.
Insel PA, Zhang L, Murray F, Yokouchi H, Zambon AC. Insel PA, et al. Among authors: yokouchi h. Acta Physiol (Oxf). 2012 Feb;204(2):277-87. doi: 10.1111/j.1748-1716.2011.02273.x. Epub 2011 May 26. Acta Physiol (Oxf). 2012. PMID: 21385327 Free PMC article. Review.
Real-World Data on Subsequent Therapy for First-Line Osimertinib-Induced Pneumonitis: Safety of EGFR-TKI Rechallenge (Osi-risk Study TORG-TG2101).
Nishioka N, Imai H, Endo M, Notsu A, Doshita K, Igawa S, Yokouchi H, Ninomiya T, Tokito T, Soda S, Fujiwara T, Asao T, Nakamichi S, Kawamura T, Inomata M, Nakashima K, Ito K, Goto Y, Umeda Y, Hirai S, Ushio R, Yokoo K, Takeda T, Fukui T, Ishihara M, Osaki T, Kubo S, Fujiwara T, Yamamoto C, Tsuda T, Tamura N, Hosokawa S, Chihara Y, Ikeda S, Furuya N, Nakahara Y, Miura S, Okamoto H. Nishioka N, et al. Among authors: yokouchi h. Target Oncol. 2024 May;19(3):423-433. doi: 10.1007/s11523-024-01048-x. Epub 2024 Apr 13. Target Oncol. 2024. PMID: 38613731 Free PMC article.
CD98 heavy chain protein is overexpressed in non-small cell lung cancer and is a potential target for CAR T-cell therapy.
Yaga M, Hasegawa K, Ikeda S, Matsubara M, Hiroshima T, Kimura T, Shirai Y, Tansri W, Uehara H, Tachikawa M, Okairi Y, Sone M, Mori H, Kogue Y, Akamine H, Okuzaki D, Kawagishi K, Kawanaka S, Yamato H, Takeuchi Y, Okura E, Kanzaki R, Okami J, Nakamichi I, Nakane S, Kobayashi A, Iwazawa T, Tokunaga T, Yokouchi H, Yano Y, Uchida J, Mori M, Komuta K, Tachi T, Kuroda H, Kijima N, Kishima H, Ichii M, Futami S, Naito Y, Shiroyama T, Miyake K, Koyama S, Hirata H, Takeda Y, Funaki S, Shintani Y, Kumanogoh A, Hosen N. Yaga M, et al. Among authors: yokouchi h. Sci Rep. 2024 Aug 2;14(1):17917. doi: 10.1038/s41598-024-68779-9. Sci Rep. 2024. PMID: 39095551 Free PMC article.
319 results